In this setting, our results strongly support that PPARγ activation by partial agonists, devoid of full agonism-related unfavourable effects, may be a strategy to induce browning of WAT and hence to treat obesity and diabetes. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.